Marex Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Marex Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.04M	Sell	4,112 -3,256	-44%	-$1.44M	0.01%	371
2026 Q1	$3.29M	Sell	7,368 -74	-1%	-$34.5K	0.02%	263
2025 Q4	$3.37M	Sell	7,442 -298	-4%	-$128K	0.02%	255
2025 Q3	$3.03M	Buy	7,740 +1,037	+15%	+$433K	0.02%	227
2025 Q2	$2.98M	Buy	+6,703	New	+$3.09M	0.03%	196
2025 Q1	–	Sell	-582	Closed	-$234K	–	863
2024 Q4	$234K	Sell	582 -205	-26%	-$95K	﹤0.01%	507
2024 Q3	$366K	Buy	+787	New	+$378K	0.01%	351
2024 Q2	–	Sell	-609	Closed	-$255K	–	728
2024 Q1	$255K	Buy	609 +6	+1%	+$2.54K	0.01%	351
2023 Q4	$245K	Buy	+603	New	+$223K	0.01%	426

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Marex Group's VRTX Position: Q2 2026 in Review

Marex Group reduced its Vertex Pharmaceuticals (VRTX) stake by 44% in Q2 2026, selling an estimated $1.44M and leaving 4,112 shares worth $2.04M. The position accounts for 0.01% of the portfolio, ranked #371.

Marex Group first reported a position in VRTX in Q4 2023 and has held it in 9 quarters since. The position peaked at $3.37M in Q4 2025. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Marex Group held 4,112 shares of Vertex Pharmaceuticals worth $2.04M as of Q2 2026.
Marex Group sold 3,256 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.44M.
Vertex Pharmaceuticals made up 0.01% of Marex Group's portfolio in Q2 2026, its #371 holding.
Marex Group first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 9 quarters since.
Marex Group's Vertex Pharmaceuticals position peaked at $3.37M in Q4 2025.
1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.